糖尿病严重威胁人类健康，胰岛移植是治疗I型糖尿病的有效手段。胰腺脱细胞生物支架可为胰岛移植物提供良好的载体。但是现有的脱细胞生物支架面临移植后血管的再生问题。我们的前期研究结果证实脱细胞支架能够在体形成血管管腔，M2型巨噬细胞参与了支架移植物后期的重塑和血管新生。但是如何有效提高支架血管新生能力，及M2型巨噬细胞参与血管新生的具体机制及其时间和空间分布情况尚待研究。基于课题组的研究基础并结合目前热点，我们提出构建交联内皮祖细胞的血管化猪胰腺脱细胞生物支架，并诱导巨噬细胞的M2型极化改造支架血管新生的微环境，联合胰岛移植治疗I型糖尿病大鼠模型的假设。通过检测复合支架的生物相容性，免疫原性；将复合支架种植胰岛细胞后植入体内，评估移植物的存活情况，血管新生情况及巨噬细胞极化情况；体内外实验探讨极化巨噬细胞对血管内皮祖细胞调控及并阐明其分子机制验证上述假设。本研究可为治疗I型糖尿病提供新的思路。

Diabetes is one of the most serious threats to human health. Islet transplantation is an effective therapy for type I diabetes.Decellularized pancreatic scaffold provides a suitable support for the islets graft. But the problem of existing scaffolds is the reconstruction of functional blood vessels. Our previous results indicated that Vascular lumen can be found in the scaffolds in vivo and M2 type macrophages participate in remodeling of the scaffolds. However, how to promote the process of vasculariztion and the specific mechanism and the temporal and.spatial distribution of macrophage subpopulation during angiogenesis is not clear. Based on our previous researches on scaffolds and islet transplantation,we hypothesized that the porcine pancreatic scaffolds which crosslink of anti-CD34 antibody to bind with endothelial progenitor cells can be used to cure the type I diabetes rats combining with inducing macrophages towards M2 type. Immunochemial staining and ELISA will be used to detect its biocompatibility and immunogenicity; After seeded with islets, assessment of the viability of grafts, polarization of.macrophages and the angiogenesis will be done;The interaction between macrophages and endothelial progenitor cell and the underlying mechanism will be elucidated in vitro and in vivo. Our study can provide a new strategy for therapy of the type I diabetes.